Gossamer Bio Inc (NASDAQ:GOSS) shares gapped up before the market opened on Monday . The stock had previously closed at $20.46, but opened at $20.48. Gossamer Bio shares last traded at $20.84, with a volume of 6998 shares traded.

A number of research analysts have weighed in on the company. Bank of America assumed coverage on Gossamer Bio in a report on Tuesday, March 5th. They set a “buy” rating and a $30.00 target price on the stock. Svb Leerink initiated coverage on Gossamer Bio in a report on Tuesday, March 5th. They set an “outperform” rating and a $30.00 target price on the stock. Barclays initiated coverage on Gossamer Bio in a research note on Tuesday, March 5th. They issued an “overweight” rating and a $27.00 price target on the stock. Evercore ISI initiated coverage on Gossamer Bio in a research note on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 price target on the stock. Finally, Leerink Swann initiated coverage on Gossamer Bio in a research note on Tuesday, March 5th. They issued an “outperform” rating on the stock. Five investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $29.25.

In other Gossamer Bio news, CFO Bryan Giraudo bought 6,000 shares of the business’s stock in a transaction on Tuesday, February 12th. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $96,000.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Russell J. Cox bought 7,200 shares of the business’s stock in a transaction on Tuesday, February 12th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $115,200.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 14,750 shares of company stock worth $236,000.

TRADEMARK VIOLATION NOTICE: This story was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2019/03/18/gossamer-bio-goss-shares-gap-up-to-20-48.html.

About Gossamer Bio (NASDAQ:GOSS)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Featured Story: Benefits of owning preferred stock

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.